NCT05795595CompletedPhase 1/2
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- First submitted
- 21 Mar 2023
- Start date
- 13 Mar 2023
- Primary completion date
- 18 Sept 2025
- Lead sponsor
- CRISPR Therapeutics AG
- Diseases
- Mesothelioma, Kidney cancer, Cervical cancer, Lung cancer, Pancreatic cancer, Gastric and esophageal cancer
- NCT number
- NCT05795595
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 19
- From 13 Mar 2023 to the primary completion date, 18 Sept 2025
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with anti-CD70 targeting agents
Other illness
- History of certain central nervous system (CNS), cardiac or pulmonary conditions.
- Presence of uncontrolled bacterial, viral, or fungal infection.
- Active HIV, hepatitis B virus or hepatitis C virus infection.
- Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.
Other
- Women who are pregnant or breastfeeding.
Who the study is looking for
- Age ≥18 years.
- Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma.
- Eastern Cooperative Oncology Group performance status 0 or 1.
- Adequate renal, liver, cardiac and pulmonary organ function.
- Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX131 infusion.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| - Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.